A New Era in Migraine Prevention

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Focusing Migraine Treatment on the Individual

Migraine Treatment Strategies

Goal of Acute and Preventive Treatment for Migraine

Indications for Migraine Preventive Treatment

Recommended Migraine Prevention Treatments: Repurposed Therapies

Lack of Persistence and Adherence to Conventional Preventive Treatments

Good Practice for Migraine Prevention

The Migraine Brain: Pain Signals Spread to Multiple Cortical Areas and Alter Their Excitability

Activation of Pain Fibers and Symptom Cascade

Proposed Mechanism for the Role of CGRP in Prolonged Activation Headache Phase of Migraine

Proposed Mechanism for Prevention of the Headache Phase of Migraine by Anti-CGRP mAbs

Anti-CGRP mAbs: Summary of Phase 3 Studies

Summary of Phase 3 Findings for the Anti-CGRP mAbs

Safety of Anti-CGRP mAbs: Similar to Placebo

Results in Patients With Previous Treatment Failures: Erenumab and LIBERTY

Reduction in MMD: Fremanezumab and FOCUS

Time to Inhibition With IV Fremanezumab: Experimental Finding

Proof of Concept of the CGRP Pathway

EHF Recommendation on Use of mAbs: Expert Opinion

EHF Recommendations for Headache Health Care Service Organization

Aids to Management of Headache Disorders in Primary Care

Several Risk Factors Predict Progression From Episodic to Chronic Headache

Setting and Practical Application

Use in Special Populations

EMA Indications for the Anti-CGRP mAbs

Discussion: Can the Course of Migraine Be Changed?

Discussion: Integrating Anti-CGRP mAbs Into Clinical Practice

Discussion: The Unknowns of CGRP

Concluding Remarks

Abbreviations